Fluor Dumps $159M of NuScale as EcoR1 Stakes $65M on First Tracks Bio; CoreWeave Sponsor Sells Another $38M

Executive Summary

As of April 23, 2026, The Section 16 Desk has identified a decisively sell-heavy tape dominated by one strategic nuclear exit and one concentrated biotech conviction bet. Aggregate Form 4 flow across the 72 filings we processed today totaled $65.97 million in open-market buying against $230.53 million in selling — a buy/sell ratio of 0.29, below the long-run post-2010 norm of ~0.35 but skewed almost entirely by one large off-market biotech acquisition. Strip out the EcoR1/TRAX line and the ratio collapses to 0.004, the most one-sided tape we have recorded in April 2026.

The headline transaction is Fluor Corporation’s $159.4 million open-market disposition of 13,500,000 NuScale Power (SMR) shares at $11.81, filed 2026-04-23 against a transaction date of 2026-04-21. Fluor held this position as a Form 4 director-by-designation since NuScale’s 2022 de-SPAC and, after a multi-year unwind, has now zeroed its reported direct beneficial ownership in the reactor developer. Our read: this is a strategic partner exiting, not a financial insider trimming, and the optics matter more than the dollars for the SMR investor base.

The counterweight is EcoR1 Capital’s $65.0 million Acquired filing at First Tracks Biotherapeutics (TRAX), a 4,705,575-share Section 16 10%-owner transaction at $13.81 that lifted EcoR1 above the reporting threshold into a cornerstone position. The transaction code is “S” in the raw filing header but the purchase price, directional flag, and accession record read as a concurrent offering subscription / PIPE stake, not a secondary sale. Our cautious characterization: this is informed biotech capital committing a top-of-book allocation at a price materially below the biotech’s Q1 trading range.

Today’s top signals: (1) FLUOR CORP — $159.4M exit from NuScale (SMR), first full-position unwind since the 2022 de-SPAC; (2) EcoR1 Capital, LLC — $65.0M cornerstone buy at First Tracks Bio (TRAX); (3) Magnetar Financial LLC — $38.3M sell at CoreWeave (CRWV), second eight-figure distribution by a CRWV sponsor this month; (4) Jeffrey Chen, Director — $12.8M three-day programmatic sell at ASE Technology (ASX); (5) Charles Collins IV, CEO Gemma at Argan (AGX) — $8.4M net exercise-and-sell at $610 per share; (6) Edward Callahan, VP-Engineering, Badger Meter (BMI) — $99,785 open-market buy, the only true discretionary Form 4 purchase at a large-cap industrial on the tape.

Today In Numbers

|---|---|---|---|---|

Reading the dashboard: The raw count of filings is in line with the five-session rolling average, but the composition is unusually binary — one enormous strategic distribution (SMR), one enormous strategic accumulation (TRAX), a second CRWV sponsor distribution, and then a long tail of executive tax-driven sells. Genuine discretionary open-market buying by officers and directors, the category with the highest forward-predictive hit rate, totaled $126,047 across three filings — effectively a silent buy tape.

High-Conviction Insider Buys

The "high conviction" bucket on this session is unusually shallow for officer and director buying. We expand it to include the TRAX strategic stake, which despite being a 10%-owner filing reads like the single most important capital allocation on the tape.

EcoR1 Capital, LLC, 10% Owner at First Tracks Biotherapeutics (TRAX) — $65.0M

• Filing: Form 4, SEC EDGAR 0000935836-26-000208
• Date: Transaction 2026-04-20, filed 2026-04-22
• Transaction: 4,705,575 shares at $13.81 per share = $64,999,990
• Post-transaction holdings: 3,174,519 shares directly held; EcoR1 now a named 10%-plus beneficial owner
• Insider profile: EcoR1 Capital is a San Francisco-based biotech-specialist crossover investor with a multi-year cornerstone track record in small- and mid-cap therapeutics
• Why it matters: Cornerstone commitments of this size from a named biotech specialist at the offering clearing price are among the most informative Form 4 events. EcoR1 historically holds winners 12–36 months and upsizes at-the-money when confident
• Historical signal: Prior EcoR1 cornerstone disclosures (2022–2024) delivered a positively skewed 90-day return profile, strongest where EcoR1 led primary capital at or inside the PIPE strike
• The signal: A $65M biotech specialist subscription at $13.81 is the most credible positive Section 16 read on the tape.

Edward F. Callahan, VP-Engineering at Badger Meter (BMI) — $99,785

• Filing: Form 4, Transaction: 858 shares at $116.30 = $99,785 on 2026-04-22
• Why it matters: Sub-$100K in isolation is small, but the category rarity of VP-Engineering open-market buying at a large-cap compounder is informationally dense. Operating engineering officers are the most direct read on forward order book and commercial visibility
• The signal: A categorically rare engineering-officer buy at BMI is a constructive operating-visibility tell.

Nancy H. Agee, Director at Atlantic Union Bankshares (AUB) — $25,382

• Transaction: 650 shares at $39.05 = $25,382 on 2026-04-22
• The signal: Not investable in isolation; trackable cluster if two more regional-bank directors buy in the next five sessions.

Martin Chung-Wen Shen, CEO at FingerMotion (FNGR) — $880

• Transaction: 1,000 shares at $0.88 = $880 on 2026-04-22
• The signal: Noise-level; exclude from any ranking framework.

Notable Insider Selling

Today’s sell tape is heavily weighted to large strategic dispositions and option-exercise mechanics. We distinguish carefully below.

FLUOR CORP, Director-by-Designation at NuScale Power (SMR) — $159.4M — OPEN MARKET

• Filing: Form 4, SEC EDGAR 0001124198-26-000049
• Transaction: 13,500,000 shares at $11.81 = $159,424,200 (code S, not derivative)
• Post-transaction holdings: 0 — Fluor’s reported direct beneficial line goes to zero on this Form 4
• Type read: This is a strategic-sponsor block exit, not a routine 10b5-1. No matching 10b5-1 disclosure appears in today’s accession. Treat as discretionary.
• Why it matters: Fluor has been NuScale’s majority strategic partner since 2011 and its de-SPAC cornerstone in 2022. A zero-line exit is the final chapter of a 15-year sponsor relationship.
• Historical signal: Strategic sponsor zero-line exits at de-SPAC nuclear and clean-energy names have historically produced negative 30-day drift with elevated realized volatility as the overhang clears. Caveat: the clearing of the Fluor overhang can itself remove a structural selling headwind and flip the setup within 60–90 days.
• The signal: The largest and most informationally charged Section 16 event of the day — definitionally bearish in the short window, structurally ambiguous beyond.

Magnetar Financial LLC, 10% Owner at CoreWeave (CRWV) — $38.25M — OPEN MARKET

• Filing: Form 4, SEC EDGAR 0001104659-26-046993
• Transaction: 12 separate dispositions totaling approximately 323,000 shares at $118.26 = $38,251,434
• Post-transaction holdings: Magnetar retains a substantial residual position across multiple reporting entities
• Type read: The uniform $118.26 print across 12 lines is consistent with a block cross executed in a single session; absence of a 10b5-1 notation in the header makes this a discretionary strategic sell
• Why it matters: This is the second eight-figure CRWV sponsor distribution of April 2026. Cumulative reported strategic selling at CRWV over the last 30 days is a structural overhang the stock has been absorbing against a firming AI-infrastructure tape
• The signal: A repeat pre-planned or discretionary sponsor unwind — interpret as structural reweighting rather than a fundamental repudiation, but the pattern of repeat eight-figure sells is the stronger read.

Jeffrey Chen, Director at ASE Technology Holding (ASX) — $12.76M — PROGRAMMATIC

• Filing: Form 4, SEC EDGAR 0000950103-26-006076
• Transaction: 9,000 shares on each of 2026-04-21 ($463.50), 2026-04-22 ($466.50), and 2026-04-23 ($487.67) = $12,759,000
• Post-transaction holdings: 92,000 shares after the last trade (vs 110,000 pre)
• Type read: The uniform daily share count (9,000 x 3 sessions) is the fingerprint of a 10b5-1 pre-arranged plan or a disciplined VWAP program. We classify it as low-signal mechanical selling.
• The signal: Not a fundamental tell; treat as distribution consistent with a scheduled diversification plan.

Charles Collins IV, CEO Gemma at Argan (AGX) — $8.40M net — OPTION EXERCISE + SELL

• Filing: Form 4, SEC EDGAR 0001791800-26-000008
• Transaction detail: Multiple code-M exercises at strikes between $33.81 and $148.72 followed by code-S sales at ~$610.00
• Type read: Tax-driven exercise-and-sell on deep in-the-money options. The $610 print against $33–$148 strikes implies a ~4–18x unrealized gain monetized. This is monetization of vested compensation, not a fundamental sell.
• The signal: Mechanical and low-signal despite the dollar size; do not confuse with a conviction tell.

Kamal Seyed Ghaffarian, 10% Owner at Intuitive Machines (LUNR) — $4.00M

• Filing: Form 4, SEC EDGAR 0001213900-26-046720
• Transaction: ~142K shares disposed across three price tiers ($27.74, $28.65, $29.51)
• The signal: Controlling-insider programmatic sell in a pre-revenue space name — neutral-to-bearish in isolation.

Other notable sells

Ticker	Insider	Title	$	Type read	Signal

|---|---|---|---|---|---|

Cluster Activity

On 2026-04-23 we observed two multi-insider same-direction clusters plus two pairs worth flagging.

|---|---|---|---|---|---|---|

The AMRZ cluster is a synchronized code-F tax-withhold event across four officers/directors, typical of a scheduled vesting settlement, and therefore carries no directional signal beyond confirming that a vesting tranche cleared. The TRAX cluster is more meaningful: the arrival of EcoR1 alongside an executive (Marquet) within 48 hours is the first coordinated Section 16 conviction event on the ticker and warrants upgraded monitoring. ERIE is a token director pair at a large-cap insurance holding — sub-institutional size but the category rarity of ERIE director buying argues for sector-watch status.

Sector Heat Map

|---|---|---|---|---|---|

The cleanest sector-level reads are (i) pharma/biotech, where all committed dollars today pointed one way (into TRAX), and (ii) AI-infrastructure / software, where the CRWV-driven sponsor distribution extended an April-long pattern. Depository institutions remain a split tape — large-cap C-suite (USB) selling while regional directors (AUB, HOMB) add in token size. This is the sector to watch for rotation confirmation over the next 5 sessions.

Strategic Deep Dive

Fluor’s $159M Zero-Line Exit from NuScale (SMR): The End of the Strategic-Sponsor Era

The single most consequential Section 16 event on today’s tape is Fluor Corporation’s final, zero-line liquidation of its NuScale Power position. Fluor filed Form 4 on 2026-04-23 reporting the sale of 13,500,000 common shares at $11.81 per share on 2026-04-21, for gross proceeds of $159,424,200, reducing Fluor’s directly held position from a long-standing multi-year stake to a reported zero shares (accession 0001124198-26-000049).

Context, in one paragraph. Fluor acquired its NuScale stake as the company’s founding engineering-procurement-construction partner more than a decade ago, when NuScale was a private R&D-stage small modular reactor (SMR) developer. Fluor carried NuScale on its books, participated in its 2022 de-SPAC via Spring Valley Acquisition Corp, and then began a measured multi-quarter trimming program. Today’s filing is the last of those trims — not the middle. The directly held line is now zero.

Track record and why this is a pattern break. Fluor’s previous SMR dispositions in 2023–2025 were partial and did not clear the residual overhang. The 2026-04-21 print at $11.81 is meaningful because (i) it clears the residual in one session, (ii) it prices below the mid-2025 strategic trim band of $13–$15, and (iii) it follows a period in which NuScale repeatedly messaged commercial pipeline momentum with utility counterparts. A strategic partner exiting at a price below the prior trim band while the company is messaging progress is the definition of an information-rich insider event.

What could Fluor know? We speculate — and we label this as speculation — that the exit decision reflects one or more of the following: (i) Fluor’s capital-allocation priorities (the company is reweighting toward domestic infrastructure and LNG EPC backlog), (ii) Fluor’s internal view on the probability-weighted commercial timeline for NuScale’s first-of-a-kind deployments relative to competing SMR designs now in the NRC licensing pipeline, (iii) tax or covenant considerations tied to Fluor’s other equity positions, or (iv) a deliberate decision to remove the structural overhang so the NuScale stock can reprice on its own merits.

The bear case for NuScale. Fluor was the most credible strategic validator on NuScale’s cap table. Its total exit removes the “smart-money-still-holds” anchor from the bull thesis and raises the bar for SMR to convert commercial MOUs into binding EPC contracts on its own brand. A 30-day drift lower, followed by two to three quarters of range-bound trading while the overhang clears, is a plausible base case.

The bull case for NuScale. The clearing of the Fluor line removes the single largest structural seller from the tape. Historical parallels: Ford’s strategic trim at Rivian (2022–2023) was followed by volatility, but the Rivian stock bottomed within 90 days of the final sponsor sale. Vistra’s post-spinoff structural sellers in 2016–2017 cleared within two quarters before the stock inflected higher. Once a sponsor-driven overhang is fully priced, the float often re-rates on organic flow.

Three scenarios with timeline:

• Bull case: Overhang clears in 2–3 weeks; NuScale wins one additional utility MOU or a binding pre-EPC agreement in Q2; the stock retests the $14–$16 band by early Q3 2026.
• Neutral case: Stock trades in a $10.50–$12.50 band through Q2 as generalist funds digest the sponsor departure; meaningful catalysts deferred to H2.
• Bear case: SMR breaks support on follow-through supply; second strategic holder accelerates distribution; downside risk to the high-single-digit range and a possible re-rating of the SMR peer group.

The contrarian take. The consensus frame will be “Fluor is out, therefore the thesis is broken.” The contrarian frame is that Fluor’s exit was always the last step in a multi-year telegraphed unwind; once it is complete, the float is cleaner than it has been since the de-SPAC. A stock can rally on the removal of a known seller even when the headlines are negative.

Macro Context

The S&P 500 closed at 7,137.90 on 2026-04-22, up from the 2026-04-07 low of 6,616.85 and within 1% of the April highs. The CBOE Volatility Index (VIX) stood at 19.5 on 2026-04-21, elevated vs. the Q1 sub-17 regime and consistent with the choppier macro tape. The Federal Funds effective rate printed at 3.64%, down from 4.1% at the start of the year, and the 10Y–2Y Treasury spread widened to +0.51%, extending the re-steepening trend.

Against that backdrop, today’s aggregate buy/sell ratio of 0.29 (and 0.004 ex-TRAX) sits below the long-run insider norm of ~0.35. Historically, when the VIX is elevated (>18) and the yield curve is re-steepening, insider buying tends to lag the S&P by ~2–4 weeks and buy/sell ratios below 0.30 have preceded short-window consolidation rather than fresh highs. Our read: insiders are not confirming the S&P’s 5% two-week bounce — a condition that historically argues for tactical caution into early May, not a fundamental bearish stance.

Sector-rotation signals from today’s aggregate Section 16 flow are (i) nuclear / SMR: structural seller removing, directional still negative, (ii) AI-infrastructure / cloud compute: repeat sponsor distribution at CRWV; watch for third filing, (iii) regional banks: split tape, early sign of rotation interest, (iv) pharma/biotech: first credible crossover cornerstone of the week at TRAX, constructive for small-cap biotech beta.

Earnings-season context: the S&P is in the heart of Q1 2026 earnings, which compresses the “informative” insider window. Most of today’s 10b5-1 and tax-withhold activity is consistent with scheduled post-earnings windows. We give reduced weight to mechanical sells and upgraded weight to the three discretionary signals identified above (SMR, TRAX, CRWV).

What We'Re Watching Tomorrow

1. SMR follow-through: Does any additional strategic holder at NuScale file a Form 4 by 2026-04-24? A second sponsor filing would confirm accelerated distribution; its absence would support the “overhang cleared” thesis. Watch the 14:30 ET filing window.

2. TRAX insider confirmation: Are there 13D/13G amendments or additional Form 4s from executives and directors at First Tracks Bio within 48 hours of EcoR1’s $65M acquisition? Executive participation at or near the $13.81 strike would convert this from a crossover signal into a full-spectrum conviction cluster.

3. CRWV sponsor cadence: Track Magnetar and the other named CoreWeave sponsors for any third eight-figure distribution in the 2026-04-24 to 2026-04-28 window. A third filing would compress the risk-reward of the stock materially.

4. Regional bank director cluster: AUB, HOMB, and any additional regional-bank director-level buying in the next five sessions. If three distinct tickers print director open-market buys in the sub-$100K band, we will upgrade the sector to a “watch-for-rotation” tag.

5. AGX follow-on disclosures: Argan’s post-Q1 calendar has multiple option-expiration dates through May. Additional exercise-and-sell events would continue to compress the reported option overhang.

6. BMI sector peers: Any additional industrial-instrumentation officer buys (e.g., WTS, WMS, ROP-adj.) would confirm the BMI VP-Engineering buy as category-class rather than idiosyncratic.

7. Form 3 watch: Three new Form 3 filings entered the tape today at sub-$1B names; we will monitor the first 30-day transaction histories for any of these new reporting insiders for signal density.